Huebner Hanna, Häberle Lothar, Müller Volkmar, Schrader Iris, Lorenz Ralf, Forstbauer Helmut, Fink Visnja, Schochter Fabienne, Bekes Inga, Mahner Sven, Jückstock Julia, Nabieva Naiba, Schneeweiss Andreas, Tesch Hans, Brucker Sara Y, Blohmer Jens-Uwe, Fehm Tanja N, Heinrich Georg, Rezai Mahdi, Beckmann Matthias W, Fasching Peter A, Janni Wolfgang, Rack Brigitte
Department of Gynecology and Obstetrics, Comprehensive Cancer Center EMN, Erlangen University Hospital, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
Biostatistics Unit, Department of Gynecology and Obstetrics, Erlangen University Hospital, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
Cancers (Basel). 2022 Mar 28;14(7):1721. doi: 10.3390/cancers14071721.
Soluble MUC1 has been discussed as a biomarker for predicting prognosis, treatment efficacy, and monitoring disease activity in breast cancer (BC) patients. Most studies in adjuvant settings have used preoperative assessment. This study, part of the SUCCESS-A trial (NCT02181101), assessed the prognostic value of soluble MUC1 before and after standard adjuvant chemotherapy. Patients with high-risk BC were treated within the SUCCESS-A trial with either three cycles of 5-fluorouracil, epirubicin, and cyclophosphamide followed by three cycles of docetaxel or three cycles of FEC followed by three cycles of docetaxel and gemcitabine. Cox regression analyses were performed to investigate the prognostic value of CA27.29 before and after chemotherapy relative to disease-free survival (DFS), along with established BC prognostic factors such as age, body mass index, tumor size, nodal status, estrogen receptor, progesterone receptor, HER2 status, and grading. Pre-chemotherapy and post-chemotherapy CA27.29 assessments were available for 2687 patients of 3754 randomized patients. Pre-chemotherapy CA27.29 assessment was associated with DFS in addition to established prognostic factors. It had no prognostic value in node-negative patients, but there was a clear association in node-positive patients. Post-chemotherapy CA27.29 assessment did not add any prognostic value, either on its own or in addition to pre-chemotherapy CA27.29 assessment.
可溶性MUC1已被作为预测乳腺癌（BC）患者预后、治疗疗效及监测疾病活动的生物标志物进行讨论。大多数辅助治疗研究采用术前评估。本研究作为SUCCESS-A试验（NCT02181101）的一部分，评估了标准辅助化疗前后可溶性MUC1的预后价值。高危BC患者在SUCCESS-A试验中接受治疗，方案为三个周期的5-氟尿嘧啶、表柔比星和环磷酰胺，随后三个周期的多西他赛，或三个周期的FEC方案，随后三个周期的多西他赛和吉西他滨。进行Cox回归分析以研究化疗前后CA27.29相对于无病生存期（DFS）的预后价值，以及已确定的BC预后因素，如年龄、体重指数、肿瘤大小、淋巴结状态、雌激素受体、孕激素受体、HER2状态和分级。3754例随机分组患者中有2687例患者可获得化疗前和化疗后CA27.29评估结果。除已确定的预后因素外，化疗前CA27.29评估与DFS相关。它在淋巴结阴性患者中无预后价值，但在淋巴结阳性患者中有明显关联。化疗后CA27.29评估无论是单独使用还是与化疗前CA27.29评估联合使用，均未增加任何预后价值。
